WESTBOROUGH, Mass.–(BUSINESS WIRE)–Kopin® Corporation (NASDAQ: KOPN), a leading developer and provider of transmissive and reflective active matrix liquid crystal and organic light emitting diode (OLED) microdisplays and display subassemblies for military, enterprise, industrial, consumer and medical products, today announced that its BDM® WVGA LCD module and A912 Driver IC have been chosen by Medisim Ltd. for its BinoVision™ goggles.
“We are delighted that Medisim Ltd. has selected our products for its BinoVision™ goggles, and want to congratulate them on their success”
“Kopin’s knowledge of microdisplays and optical modules was very apparent to us during our process of selecting a near-to-eye LCD,” said Ilan Vadai, CEO, Medisim Ltd. “Kopin’s WVGA module and A912 ASIC were key components necessary to bring BinoVision™ to fruition. Kopin’s displays provide a high level of brightness – a key requirement for our application. In addition, with the displays and optics precisely aligned and securely packaged in a binocular module, the ease of integration was unmatched.”Medisim Ltd., based in Israel, developed the novel and patented product – BinoVision™, aiming to treat Amblyopia (Lazy Eye). The binocular head-mounted video goggle connects to most streaming video sources (computer, TV, game console, etc.) and uses the content (movies, cartoons, games, music videos, TV shows) to enable brain stimulation. BinoVision™ is content agnostic, so compliance is high. A published clinical study results of the technology showed that dichoptic stimulation of the visual system can significantly improve visual function in just 4 weeks. A feasibility study at Indiana University suggested BinoVision™ goggles, with some modifications, may also be used in the future for glaucoma. In a published study, the technology demonstrated increasing ocular blood flow and retinal perfusion both in glaucoma patients and healthy subjects.
“We are delighted that Medisim Ltd. has selected our products for its BinoVision™ goggles, and want to congratulate them on their success,” said Greg Truman, Head of Industrial and Enterprise Displays, Kopin. “We are excited by the increased interest in our microdisplays for medical products and believe a variety of applications such as surgical, procedural, ophthalmic and others can benefit from the integration of our near-to-eye microdisplays.”
Headquartered in Westborough, Massachusetts, Kopin and its subsidiaries offer a variety of industry leading microdisplay product lines, including LCD, OLED and FLCoS displays. Kopin’s BDM-WVGA (LCD) delivers a large (42″-diagonal size viewed at 6.5-foot distance), crisp image. The lightweight (16g), compact binocular display module integrates two 16: 9 widescreen CyberDisplay® WVGA LVD (854×480 resolution) color filter displays, LED backlights and a pair of pre-aligned high-quality lenses (30 degree field of view) into plastic housing. The BDM-WVGA is driven by Kopin’s A912 controller IC. The BDM-WVGA is a drop in solution, meant to speed up eyewear development and enable OEMs to design-in products quickly and efficiently.
Kopin, CyberDisplay and BDM are registered trademarks of Kopin Corporation.
Kopin Corporation is a leading developer and provider of innovative display and optical technologies sold as critical components and subassemblies for military, industrial and consumer products. Kopin’s technology portfolio includes ultra-small Active Matrix Liquid Crystal displays (AMLCD), Liquid Crystal on Silicon (LCOS) displays and Organic Light Emitting Diode (OLED) displays, a variety of optics, and low-power ASICs. For more information, please visit Kopin’s website at www.kopin.com.
About Medisim Ltd.
Medisim Ltd. is a developer and manufacturer of innovative diagnostic medical devices. Founded in 1995, Medisim’s headquarters and manufacturing plant are based in Israel, with subsidiaries in the USA and Hong Kong. As an R&D centric company, continually allocating substantial resources into developing innovative, cost-efficient and highly scalable medical solutions, Medisim is proud of its innovative spirit and contribution to enhancing peoples’ health. For more information, please visit Medisim website at: https://www.medisim.co.il
Statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the safe harbor created by such sections. Words such as “expects,” “believes,” “can,” “will,” “estimates,” and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements. We caution readers not to place undue reliance on any such “forward-looking statements,” which speak only as of the date made, and advise readers that these forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by us that are difficult to predict. These forward-looking statements may include statements with respect to: Our belief that a variety of applications such as surgical, procedural, ophthalmic and others can benefit from the integration of our near-to-eye microdisplays. Various factors, some of which are beyond our control, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. All such forward-looking statements, whether written or oral, and whether made by us or on our behalf, are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as may otherwise be required by the federal securities laws. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations are described in Part I, Item 1A. Risk Factors; Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and other parts of our Annual Report on Form 10-K for the fiscal year ended December 28, 2019, or as updated from time to time in the Company’s Securities and Exchange Commission filings.